Formula I FGFR Inhibitor Design for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FGFR inhibitors suffer from poor selectivity, often inhibiting other kinases like c-kit and PDGFRa, which raises concerns about their therapeutic window and effectiveness in treating FGFR-related diseases.
Innovation Solution
Development of a compound of formula (I) that acts as a selective FGFR inhibitor, with specific substituents and structures designed to target FGFR pathways without affecting other kinases, along with a method for its preparation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing FGFR inhibitors are used, then FGFR activity is inhibited, but other kinases like c-kit and PDGFRa are also inhibited, reducing therapeutic window
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures (formula I) that have customized substituents (R1-R7 groups) to achieve selective binding to FGFR. The compound structure includes a pyridine ring with specific substituents that create unique interaction patterns with FGFR, allowing selective inhibition without affecting other kinases like c-kit and PDGFRa.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and chemical groups) to optimize selectivity. The invention modifies chemical parameters of the inhibitor structure to enhance FGFR specificity while maintaining inhibitory activity, thereby improving the therapeutic window by reducing off-target effects.
2Object-affected harmful factors
If selective FGFR inhibitors are developed, then therapeutic window is improved, but compound structure and preparation complexity increase
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core pyridine ring structure and variable substituent groups (R1-R7). This modular approach allows systematic exploration of structural variations to achieve selectivity while managing synthesis complexity through standardized building blocks.
Solution Approach 2:
The patent employs universality by creating a versatile inhibitor framework (formula I) that can generate multiple selective FGFR inhibitors through variation of substituents. The core structure serves as a universal platform that maintains FGFR binding capability while allowing customization to optimize selectivity and reduce off-target effects.
3Adaptability or versatility
If FGFR inhibitors are used to treat various diseases, then therapeutic applications expand, but selectivity and safety concerns arise
Solution Approach 1:
The patent applies universality by developing a selective FGFR inhibitor platform (formula I) that can be applied across multiple disease indications including cancers, myeloproliferative disorders, skeletal diseases, and hypophosphatemia. The consistent selective mechanism provides reliable FGFR inhibition while maintaining safety across different patient populations and disease states.
Data Source
AI summary
A compound having a structure of formula (I) and a preparation method therefor, and a use of the compound serving as an FGFR inhibitor for treating tumors, cancers, myeloproliferative diseases, bone or chondrocyte disorders, and hypophosphatemia.